6533b827fe1ef96bd1286da6

RESEARCH PRODUCT

PO-298 MYC favours the onset of tumour initiating cells by inducing epigenetic reprogramming of mammary epithelial cells towards a stem cell-like state

subject

description

ABSTRACT Introduction Breast cancer consists of highly heterogenous tumours whose cell of origin resulted difficult to be defined. Recent findings highlighted the possibility that tumor-initiating cells (TICs) may arise from dedifferentiation of lineage-committed cells, by reactivation of multipotency in response to oncogenic insults. MYC is the most frequently amplified oncogene in breast cancer and the activation of MYC pathway has been associated with the basal-like subtype, which is characterised by poor survival and lack of a specific therapeutic strategy. Although MYC has been considered a driver oncogene in breast cancer, its mechanism of action in tumour initiation has been poorly addressed. Material and methods To evaluate the role of MYC in perturbing cell identity of somatic cells, we transduced hTERT-immortalised human mammary epithelial cells (IMEC) with a retroviral vector expressing low levels of the exogenous c-Myc. The effect of MYC overexpression was evaluated by performing morphological analysis and gene expression profiling. To verify whether MYC overexpression could enrich for cells with functional stem cell-like properties, we performed mammospheres assay. ChIP-seq analyses were performed to profile chromatin modifications and MYC binding in IMEC WT, -MYC and mammospheres. To determine whether MYC-reprogrammed IMEC were enriched for TICs, we performed in vivo injection in NOD/SCID mice and assessed long-term tumorigenic potential by performing serial transplantation assay. To assess the clinical relevance of our findings, we investigated the expression of MYC-dependent oncogenic signature in a database of breast cancer patients. Results and discussions Overexpression of MYC induces transcriptional repression of lineage-specifying transcription factors, causing decommissioning of luminal-specific enhancers. Of note, MYC-driven dedifferentiation supports the onset of a basal/stem cell-like state by inducing the activation of de novo enhancers, which drive the transcriptional activation of oncogenic pathways. MYC-driven epigenetic reprogramming favours the formation and maintenance of TICs endowed with metastatic capacity. Moreover, oncogenic pathways activated by MYC-modulated enhancers are associated with basal-like breast cancer in patients with a poor prognosis. Conclusion MYC-driven tumour initiation relies on a cell reprogramming process, which is mediated by activation of MYC-dependent oncogenic enhancers, thus establishing a therapeutic rational for treating basal-like breast cancers.